Bruce N Rehlaender

US Patent:

6867183, Mar 15, 2005

Filed:

Sep 5, 2002

Appl. No.:

10/235381

Inventors:

Richard Soltero - Holly Springs NC, US
Balasingam Radhakrishan - Chapel Hill NC, US
Nnochiri N. Ekwuribe - Cary NC, US
Bruce Rehlaender - Chapel Hill NC, US
Anthony Hickey - Chapel Hill NC, US
Li Li Bovet - Chapel Hill NC, US

Assignee:

Nobex Corporation - Durham NC

International Classification:

A61K038/28
C07K014/62

US Classification:

514 3, 514784, 530303

Abstract:

Pharmaceutical compositions that include an insulin drug-oligomer conjugate, a fatty acid component, and a bile salt component are described. The insulin drug is covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component are present in a weight-to-weight ratio of between 1:5 and 5:1. Methods of treating an insulin deficiency in a subject in need of such treatment using such pharmaceutical compositions are also provided, as are methods of providing such pharmaceutical compositions.

US Patent:

7030082, Apr 18, 2006

Filed:

Mar 5, 2003

Appl. No.:

10/382069

Inventors:

Richard Soltero - Holly Springs NC, US
Nnochiri N. Ekwuribe - Cary NC, US
Foyeke Opawale - Raleigh NC, US
Bruce Rehlaender - Chapel Hill NC, US
Anthony Hickey - Chapel Hill NC, US
Li Li Bovet - Chapel Hill NC, US

Assignee:

Nobex Corporation - Durham NC

International Classification:

A61K 38/02
A61K 38/23

US Classification:

514 2, 514 12, 514 21, 514784, 514785

Abstract:

Pharmaceutical compositions that include a drug and/or drug-oligomer conjugate, a fatty acid component and a bile salt component, or a bile salt component without a fatty acid component are described. The drug can be covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component, when together, can be present in a weight-to-weight ratio of between 1:15 and 15:1 or any value between. Methods of treating diseases in a subject in need of such treatment using the pharmaceutical compositions of this invention are also provided, as well as methods of providing such pharmaceutical compositions.

US Patent:

7196059, Mar 27, 2007

Filed:

Mar 5, 2003

Appl. No.:

10/382155

Inventors:

Richard Soltero - Holly Springs NC, US
Balasingam Radhakrishan - Chapel Hill NC, US
Nnochiri N. Ekwuribe - Cary NC, US
Bruce Rehlaender - Chapel Hill NC, US
Anthony Hickey - Chapel Hill NC, US
Li Li Bovet - Chapel Hill NC, US

Assignee:

Biocon Limited - Bangalore

International Classification:

A61K 38/28
C07K 14/62

US Classification:

514 3, 514784, 530303

Abstract:

Pharmaceutical compositions that include insulin, an insulin drug-oligomer conjugate, a fatty acid component, and a bile salt component or a bile salt component without a fatty acid component are described. The insulin drug is covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component, when together, can be present in a weight-to-weight ratio of between 1:15 and 15:1. Methods of treating an insulin deficiency in a subject in need of such treatment using such pharmaceutical compositions are also provided, as are methods of providing such pharmaceutical compositions.

US Patent:

6770625, Aug 3, 2004

Filed:

Sep 5, 2002

Appl. No.:

10/235284

Inventors:

Richard Soltero - Holly Springs NC
Nnochiri N. Ekwuribe - Cary NC
Foyeke Opawale - Raleigh NC
Bruce Rehlaender - Chapel Hill NC
Anthony Hickey - Chapel Hill NC
Li Li Bovet - Chapel Hill NC

Assignee:

Nobex Corporation - Durham NC

International Classification:

A61K 3802

US Classification:

514 12, 514 3, 514 21, 514784, 514808

Abstract:

Pharmaceutical compositions that include a drug-oligomer conjugate, a fatty acid component, and a bile salt component are described. The drug is covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component are present in a weight-to-weight ratio of between 1:5 and 5:1. Methods of treating diseases in a subject in need of such treatment using such pharmaceutical compositions are also provided, as are methods of providing such pharmaceutical compositions.

US Patent:

20210353661, Nov 18, 2021

Filed:

Mar 29, 2021

Appl. No.:

17/215491

Inventors:

- Cambridge MA, US
Angelos DOVLETOGLOU - Hamilton MA, US
Bruce REHLAENDER - Lake Oswego OR, US

International Classification:

A61K 31/7076
A61K 9/00
A61K 47/40
A61K 9/08

Abstract:

The present invention provides injectable formulations of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof and methods for treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders.

US Patent:

20210267739, Sep 2, 2021

Filed:

Oct 6, 2020

Appl. No.:

17/064370

Inventors:

- Wilson WY, US
Adam HELLER - Austin TX, US
Bruce REHLAENDER - Lake Oswego OR, US
John SPIRIDIGLIOZZI - West Roxbury MA, US

International Classification:

A61C 19/06
A61K 9/00
A61K 31/198

Abstract:

The invention features a drug delivery device held in the mouth and continuously administering either a fluid comprising drug dissolved and/or dispersed in water or in a non-toxic liquid, or a drug in solid form.

US Patent:

20210251887, Aug 19, 2021

Filed:

Dec 22, 2020

Appl. No.:

17/130936

Inventors:

- Cambridge MA, US
Angelos DOVLETOGLOU - Hamilton MA, US
Steve WALD - Valley Cottage NY, US
Bruce REHLAENDER - Lake Oswego OR, US

International Classification:

A61K 9/00
A61K 31/7076
A61P 35/02
A61K 9/08
A61K 47/02
A61K 47/12
A61K 47/26
A61K 47/40

Abstract:

The present invention provides injectable formulations of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof and methods for treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders.

US Patent:

20210154146, May 27, 2021

Filed:

Feb 4, 2021

Appl. No.:

17/167714

Inventors:

- Boston MA, US
Bruce REHLAENDER - Lake Oswego OR, US
Roch THIBERT - Mont-Royal, CA

International Classification:

A61K 9/16
A61K 9/48
A61K 9/00
A61K 31/439
A61K 31/454

Abstract:

Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.